

Daniel Baumgart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8208531/publications.pdf>

Version: 2024-02-01

67
papers

11,705
citations

117453

34
h-index

91712

69
g-index

73
all docs

73
docs citations

73
times ranked

14124
citing authors

#	ARTICLE	IF	CITATIONS
1	P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn's disease and complex perianal fistulas. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i536-i537.	0.6	5
2	Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. <i>Scientific Reports</i> , 2022, 12, 2748.	1.6	38
3	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 914-929.	0.6	29
4	Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1320-1329.	1.9	19
5	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1302-1315.	13.9	137
6	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	1.9	87
7	Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3985-3992.	1.1	1
8	Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system. <i>Npj Digital Medicine</i> , 2020, 3, 114.	5.7	52
9	Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 405-410.	1.4	15
10	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1663-1672.	2.4	437
11	An overview of clinical decision support systems: benefits, risks, and strategies for success. <i>Npj Digital Medicine</i> , 2020, 3, 17.	5.7	992
12	Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. <i>Endoscopy</i> , 2019, 51, 73-84.	1.0	65
13	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	0.6	958
14	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 273-284.	0.6	250
15	Improved high-quality colon cleansing with 1L NER1006 versus 2L polyethylene glycol+ascorbate or oral sulfate solution. <i>Digestive and Liver Disease</i> , 2019, 51, 1671-1677.	0.4	12
16	Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). <i>Cytotherapy</i> , 2019, 21, 824-839.	0.3	12
17	Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 473-483.	0.2	11
18	A80 ADHERENCE TO GUIDELINES AND BEST PRACTICES FOR IBD FLARE MANAGEMENT AND CORTICOSTEROID ADMINISTRATION: A RETROSPECTIVE CHART REVIEW. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 160-162.	0.1	0

#	ARTICLE	IF	CITATIONS
19	A110 CLINICAL DECISION SUPPORT SYSTEM FOR IBD FLARE MANAGEMENT AND CORTICOSTEROID ADMINISTRATION: PRELIMINARY RESULTS FROM AN INTERRUPTED TIME SERIES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 219-220.	0.1	0
20	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019, 10, 279.	1.6	89
21	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	0.6	331
22	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating \hat{I}^{27+} T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	0.6	24
23	Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 752-754.e1.	0.6	24
24	Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. <i>Frontiers in Immunology</i> , 2018, 9, 1959.	2.2	13
25	Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 93-103.	0.7	16
26	Effectiveness and Safety of Vedolizumab in Anti-TNF-Na \tilde{v} e Patients With Inflammatory Bowel Diseaseâ€”A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56
27	Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 386-388.	1.9	20
28	Vedolizumab safety in pregnancy and newborn outcomes. <i>Gut</i> , 2017, 66, 1866-1867.	6.1	24
29	Tablet computer enhanced training improves internal medicine exam performance. <i>PLoS ONE</i> , 2017, 12, e0172827.	1.1	31
30	Autoimmunity in Crohn's Diseaseâ€”A Putative Stratification Factor of the Clinical Phenotype. <i>Advances in Clinical Chemistry</i> , 2016, 77, 77-101.	1.8	24
31	Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 259-270.	1.9	34
32	Vedolizumab induction therapy for inflammatory bowel disease in clinical practice â€” a nationwide consecutive German cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1090-1102.	1.9	155
33	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	6.3	771
34	Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 812-820.	0.6	35
35	Association Between Response to Etrolizumab and Expression of Integrin $\hat{I}\pm E$ and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133
36	Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 31-37.	0.6	20

#	ARTICLE	IF	CITATIONS
37	Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education. <i>Gut</i> , 2016, 65, 535-536.	6.1	4
38	The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. <i>PLoS ONE</i> , 2016, 11, e0147364.	1.1	11
39	Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab. <i>Drug Design, Development and Therapy</i> , 2015, 9, 147.	2.0	7
40	US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. <i>Radiology</i> , 2015, 275, 889-899.	3.6	111
41	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2014, 384, 309-318.	6.3	421
42	Crohn's disease. <i>Lancet</i> , The, 2012, 380, 1590-1605.	6.3	1,722
43	Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. <i>Inflammopharmacology</i> , 2012, 20, 1-18.	1.9	172
44	Probe-Based Confocal Laser Microscopy Identifies Criteria Predictive of Active Celiac Sprue. <i>Digestive Diseases and Sciences</i> , 2012, 57, 451-457.	1.1	5
45	Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2011, 166, 46-54.	1.1	62
46	Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2512-2520.	0.9	53
47	Smartphones in Clinical Practice, Medical Education, and Research. <i>Archives of Internal Medicine</i> , 2011, 171, 1294.	4.3	62
48	Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. <i>Evidence-Based Medicine</i> , 2011, 16, 71-72.	0.6	3
49	Endoscopic Surveillance in Crohn's Disease and Ulcerative Colitis: Who Needs What and When?. <i>Digestive Diseases</i> , 2011, 29, 32-35.	0.8	8
50	Prospective randomized open-label multicenter phase I/II dose escalation trial of vedolizumab (HuM291) in severe steroid-refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 620-629.	0.9	46
51	How many lives does an ulcerative colitis patient have?. <i>Lancet</i> , The, 2010, 376, 928.	6.3	2
52	CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 571-6.	2.3	2
53	Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Vedolizumab (HuM291) in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 868-876.	0.2	26
54	Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2009, 157, 423-436.	1.1	77

#	ARTICLE	IF	CITATIONS
55	The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis. Deutsches Ärzteblatt International, 2009, 106, 123-33.	0.6	64
56	Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. The Cochrane Library, 2008, , CD007216.	1.5	42
57	What's new in inflammatory bowel disease in 2008?. World Journal of Gastroenterology, 2008, 14, 329.	1.4	16
58	Inflammatory bowel disease: cause and immunobiology. Lancet, The, 2007, 369, 1627-1640.	6.3	1,656
59	Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, The, 2007, 369, 1641-1657.	6.3	1,593
60	Virchow's node. Lancet, The, 2007, 370, 1568.	6.3	9
61	The c.1-260C>T Promoter Variant of CD14 but Not the c.896A>G (p.D299G) Variant of Toll-Like Receptor 4 (TLR4) Genes Is Associated with Inflammatory Bowel Disease. Digestion, 2007, 76, 196-202.	1.2	33
62	Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut, 2005, 54, 228-236.	6.1	108
63	Personal digital assistants in health care: experienced clinicians in the palm of your hand?. Lancet, The, 2005, 366, 1210-1222.	6.3	127
64	Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointestinal Endoscopy, 2005, 61, 473-475.	0.5	41
65	Current Biological Therapies for Inflammatory Bowel Disease. Current Pharmaceutical Design, 2004, 10, 4127-4147.	0.9	15
66	Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome. American Family Physician, 2003, 68, 151-2.	0.1	0
67	Intestinal barrier function. Current Opinion in Clinical Nutrition and Metabolic Care, 2002, 5, 685-694.	1.3	204